E-viri
PDF
Recenzirano
Odprti dostop
-
Arendrup, M.C.; Meletiadis, J.; Mouton, J.W.; Guinea, J.; Cuenca-Estrella, M.; Lagrou, K.; Howard, S.J.; Arendrup, M.C.; Meletiadis, J.; Howard, S.J.; Mouton, J.; Guinea, J.; Lagrou, K.; Arikan-Akdagli, S.; Barchiesi, F.; Hamal, P.; Järv, H.; Lass-Flörl, C.; Mares, M.; Matos, T.; Muehlethaler, K.; Rogers, T.R.; Torp Andersen, C.; Verweij, P.
Clinical microbiology and infection, June 2016, 2016-Jun, 2016-06-00, 20160601, Letnik: 22, Številka: 6Journal Article
The Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST) has determined breakpoints for isavuconazole and Aspergillus and for itraconazole and Candida spp., released a new document summarizing existing and new minimum inhibitory concentration ranges for quality control strains and revised the method documents for yeast and mould susceptibility testing. This technical note is based on the EUCAST isavuconazole and itraconazole rationale documents, version 1.0 of the routine and extended internal quality control for antifungal susceptibility testing as recommended by EUCAST, and the E.Def 7.3, E.Def 9.2 and E.Def 9.3 method documents (http://www.eucast.org).
